Puriblood Medical Co., Ltd.

Taipei Exchange 6847.TWO

Puriblood Medical Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2023: 0.29

Puriblood Medical Co., Ltd. Debt to Equity Ratio is 0.29 for the year ending December 31, 2023, a 17.33% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.
  • Puriblood Medical Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2022 was 0.24, a 72.57% change year over year.
  • Puriblood Medical Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2021 was 0.14, a -40.06% change year over year.
  • Puriblood Medical Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2020 was 0.23, a -84.24% change year over year.
  • Puriblood Medical Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2019 was 1.49.
Key data
Date Debt to Equity Ratio Debt to Income Ratio Debt to Tangible Net Worth Ratio Dividend Coverage Ratio
Market news
Taipei Exchange: 6847.TWO

Puriblood Medical Co., Ltd.

CEO Dr. Luke Chen
IPO Date Nov. 5, 2021
Location
Headquarters No.11, Gongye East 9th Road
Employees 42
Sector Health Care
Industries
Biotechnology Pharmaceuticals
Description

Puriblood Medical Co., Ltd. develops and sells blood cell separation products in Taiwan. The company offers leukocyte reduction filters for red blood cells, platelets, and whole blood, as well as real-time filtration sets for whole blood. It also offers Devin blood fractionation membrane filters and Minipuri cell screening syringe filters. In addition, the company develops P-Tex Technology, which is composed by bio-inspired molecular formula – zwitterionic copolymer structure. Puriblood Medical Co., Ltd. was founded in 2016 and is based in Hsinchu City, Taiwan.

StockViz Staff

January 15, 2025

Any question? Send us an email